A Phase 2 interventional study of dimethyl fumarate and tetanus diphtheria toxoids vaccine in Relapsing Forms of Multiple Sclerosis, sponsored by Biogen. Completed at 14 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-06-02.
Sponsored by Biogen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis — 1 open to participants now, 1 under way, 1 of them phase 3. Dimethyl Fumarate · Multiple Sclerosis.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, this one is the 13th largest by enrollment, is one of 7 that started in 2015, is one of 3 in phase 2, and was the 10th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →1 of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis is open now. Recruiting first, the newest first:
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 7 started in 2015.
This study's enrollment of 71 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 86 across the 22 interventional studies. Of the 17 that completed or were terminated, 11 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
127 studies in Multiple Sclerosis by Biogen: 2 open now, 4 under way, 1 of them phase 3. Of 119 finished, 36 (30%) have results posted.
Among the 127 studies in Multiple Sclerosis by Biogen, this one is the 53rd largest by enrollment of the 79 interventional ones that give a count, is one of 11 that started in 2015, is one of 16 in phase 2, and was the 79th registered.
Biogen’s Multiple Sclerosis studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 127 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012) versus those treated with non pegylated interferon (IFN).
Secondary objective is to evaluate the immune response to vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) [a mostly T cell-independent humoral response] and meningococcal polysaccharide diphtheria conjugate vaccine, quadrivalent (MCV4) [T cell-dependent neoantigen response].
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order: Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL
Biological: tetanus diphtheria toxoids vaccine · Biological: 23-valent pneumococcal polysaccharide vaccine · Biological: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) · Drug: non-pegylated interferon
Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order: Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL
Drug: dimethyl fumarate · Biological: tetanus diphtheria toxoids vaccine · Biological: 23-valent pneumococcal polysaccharide vaccine · Biological: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)
Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.
Also known as: DMF, BG00012, Tecfidera
Administered as described in the treatment arm
Also known as: Td, Tenivac
Administered as described in the treatment arm
Also known as: Pneumovax 23, PPSV23
Administered as described in the treatment arm
Also known as: MCV4, Menveo
Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
Also known as: IFN
Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level
Percentage of participants with a ≥ 2-fold rise in anti-tetanus serum immunoglobulin G (IgG) levels (responders) from prevaccination to 4 weeks after Td vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Percentage of Tetanus Responders (≥ 4-Fold Rise) at Day 28 Compared to Prevaccination Level
Percentage of participants with a ≥ 4-fold rise in anti-tetanus serum IgG levels (responders) from prevaccination to 4 weeks after Td vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Percentage of Pneumococcal Serotype 3 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level
Percentage of participants with a ≥ 2-fold rise in anti-pneumococcal serum IgG levels against serotype 3 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Percentage of Pneumococcal Serotype 3 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level
Percentage of participants with a ≥ 4-fold rise in anti-pneumococcal serum IgG levels against serotype 3 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Percentage of Pneumococcal Serotype 8 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level
Percentage of participants with a ≥ 2-fold rise in anti-pneumococcal serum IgG levels against serotype 8 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Percentage of Pneumococcal Serotype 8 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level
Percentage of participants with a ≥ 4-fold rise in anti-pneumococcal serum IgG levels against serotype 8 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Percentage of Meningococcal Serogroup C Responders (≥ 2-Fold Rise) Compared to Prevaccination Level
Percentage of participants with a ≥ 2-fold rise in anti-meningococcal serum IgG levels against serotype C from prevaccination to 4 weeks after MCV4 vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Percentage of Meningococcal Serogroup C Responders (≥ 4-Fold Rise) Compared to Prevaccination Level
Percentage of participants with a ≥ 4-fold rise in anti-meningococcal serum IgG levels against serotype C from prevaccination to 4 weeks after MCV4 vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Ratio of Serum Tetanus Level at Day 28 to Prevaccination
Median serum titer ratios from prevaccination to 4 weeks after Td vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Ratio of Serum Pneumococcal Antibodies (Serotype 3) Level at Day 28 to Prevaccination
Median serum titer ratios from prevaccination to 4 weeks after PPSV23 vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Ratio of Serum Pneumococcal Antibodies (Serotype 8) Level at Day 28 to Prevaccination
Median serum titer ratios from prevaccination to 4 weeks after PPSV23 vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Ratio of Serum Meningococcal Antibodies (Serogroup C) Level at Day 28 to Prevaccination
Median serum titer ratios from prevaccination to 4 weeks after MCV4 vaccination.
Time frame: Up to Week 4 (Day 28) postvaccination
Number of Participants Experiencing Vaccination-Emergent Adverse Events (AEs) and Serious AEs
An AE was any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, could have jeopardized the participant or required intervention to prevent one of the other outcomes listed in the definition above.
Time frame: Day 1 to Week 4
Number of Participants With Shifts From Baseline in Hematology
Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high.
Time frame: Screening to Week 4
Number of Participants With Shifts From Baseline in Blood Chemistry
Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high.
Time frame: Screening to Week 4
Number of Participants With Abnormalities in Vital Signs
Temperature increase: \> 38 celcius (C) or ≥ 1 C increase from baseline. Pulse increase: \> 120 beats per minute (bpm) or \> 20 bpm increase from baseline. Pulse decrease: \< 50 bpm or \> 20 bpm decrease from baseline. Systolic blood pressure (SBP) increase: \> 180 millimeters of mercury (mmHg) or \> 40 mmHg from baseline. SBP decrease: \< 90 mmHg or \> 30 mmHg decrease from baseline. Diastolic blood pressure (DBP) increase: \> 105 mmHg or \> 30 mmHg increase from baseline. DBP decrease: \< 50 mmHg or \> 20 mmHg decrease from baseline.
Time frame: Screening to Week 4
| Milestone | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Started | 33 | 38 |
| Completed | 33 | 38 |
| Not completed | 0 | 0 |
Percentage of participants with a ≥ 2-fold rise in anti-tetanus serum immunoglobulin G (IgG) levels (responders) from prevaccination to 4 weeks after Td vaccination.
| percentage of participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level | 73 (54 to 87) | 68 (51 to 82) |
Percentage of participants with a ≥ 4-fold rise in anti-tetanus serum IgG levels (responders) from prevaccination to 4 weeks after Td vaccination.
| percentage of participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Percentage of Tetanus Responders (≥ 4-Fold Rise) at Day 28 Compared to Prevaccination Level | 61 (42 to 77) | 42 (26 to 59) |
Percentage of participants with a ≥ 2-fold rise in anti-pneumococcal serum IgG levels against serotype 3 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.
| percentage of participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Percentage of Pneumococcal Serotype 3 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level | 79 (61 to 91) | 66 (49 to 80) |
Percentage of participants with a ≥ 4-fold rise in anti-pneumococcal serum IgG levels against serotype 3 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.
| percentage of participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Percentage of Pneumococcal Serotype 3 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level | 70 (51 to 84) | 47 (31 to 64) |
Percentage of participants with a ≥ 2-fold rise in anti-pneumococcal serum IgG levels against serotype 8 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.
| percentage of participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Percentage of Pneumococcal Serotype 8 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level | 88 (72 to 97) | 95 (82 to 99) |
Percentage of participants with a ≥ 4-fold rise in anti-pneumococcal serum IgG levels against serotype 8 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.
| percentage of participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Percentage of Pneumococcal Serotype 8 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level | 85 (68 to 95) | 82 (66 to 92) |
Percentage of participants with a ≥ 2-fold rise in anti-meningococcal serum IgG levels against serotype C from prevaccination to 4 weeks after MCV4 vaccination.
| percentage of participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Percentage of Meningococcal Serogroup C Responders (≥ 2-Fold Rise) Compared to Prevaccination Level | 53 (35 to 71) | 53 (36 to 69) |
Percentage of participants with a ≥ 4-fold rise in anti-meningococcal serum IgG levels against serotype C from prevaccination to 4 weeks after MCV4 vaccination.
| percentage of participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Percentage of Meningococcal Serogroup C Responders (≥ 4-Fold Rise) Compared to Prevaccination Level | 38 (21 to 56) | 37 (22 to 54) |
Median serum titer ratios from prevaccination to 4 weeks after Td vaccination.
| ratio | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Ratio of Serum Tetanus Level at Day 28 to Prevaccination | 6.128 (2.828 to 8.139) | 4.463 (1.955 to 8.244) |
Median serum titer ratios from prevaccination to 4 weeks after PPSV23 vaccination.
| ratio | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Ratio of Serum Pneumococcal Antibodies (Serotype 3) Level at Day 28 to Prevaccination | 9.667 (4.537 to 18.000) | 4.741 (2.000 to 11.000) |
Median serum titer ratios from prevaccination to 4 weeks after PPSV23 vaccination.
| ratio | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Ratio of Serum Pneumococcal Antibodies (Serotype 8) Level at Day 28 to Prevaccination | 27.000 (12.750 to 49.286) | 13.845 (6.000 to 28.250) |
Median serum titer ratios from prevaccination to 4 weeks after MCV4 vaccination.
| ratio | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Ratio of Serum Meningococcal Antibodies (Serogroup C) Level at Day 28 to Prevaccination | 3.300 (1.000 to 11.159) | 3.408 (1.000 to 8.600) |
An AE was any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, could have jeopardized the participant or required intervention to prevent one of the other outcomes listed in the definition above.
| participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Any Event | 18 | 16 |
| Moderate or Severe Event | 9 | 7 |
| Severe Event | 2 | 0 |
| Event Related to Existing Therapy | 3 | 3 |
| Serious Event | 0 | 0 |
| Serious Event Related to Existing Therapy | 0 | 0 |
| Serious Event Related to Td Vaccine | 0 | 0 |
| Serious Event Related to PPSV23 Vaccine | 0 | 0 |
| Serious Event Related to MCV4 Vaccine | 0 | 0 |
| Withdrew From Study Due to an Event | 0 | 0 |
Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high.
| participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Hemoglobin: Shift to Low; n=28, 36 | 1 | 0 |
| Hemoglobin: Shift to High; n=32, 38 | 0 | 0 |
| Hematocrit: Shift to Low; n=31, 37 | 2 | 1 |
| Hematocrit: Shift to High; n=32, 38 | 0 | 0 |
| Red Blood Cell Count: Shift to Low; n=25, 32 | 1 | 4 |
| Red Blood Cell Count: Shift to High; n=33, 37 | 0 | 0 |
| White Blood Cell Count: Shift to Low; n=27, 30 | 2 | 4 |
| White Blood Cell Count: Shift to High; n=33, 38 | 2 | 0 |
| Neutrophils: Shift to Low; n=27, 34 | 3 | 2 |
| Neutrophils: Shift to High; n=33, 37 | 2 | 0 |
| Basophils: Shift to Low; n=33, 38 | 0 | 0 |
| Basophils: Shift to High; n=33, 38 | 0 | 0 |
| Monocytes: Shift to Low; n=33, 38 | 0 | 2 |
| Monocytes: Shift to High; n=33, 38 | 2 | 0 |
| Lymphocytes: Shift to Low; n=33, 22 | 4 | 1 |
| Lymphocytes: Shift to High; n=33, 38 | 0 | 0 |
| Eosinophils: Shift to Low; n=33, 38 | 0 | 0 |
| Eosinophils: Shift to High; n=33, 38 | 0 | 0 |
| Platelet Count: Shift to Low; n=31, 38 | 1 | 0 |
| Platelet Count: Shift to High; n=32, 37 | 0 | 0 |
Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high.
| participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Alanine Aminotransferase: Shift to Low; n=33, 38 | 0 | 0 |
| Alanine Aminotransferase: Shift to High; n=30, 35 | 2 | 1 |
| Aspartate Aminotransferase: Shift to Low; n=33, 37 | 0 | 0 |
| Aspartate Aminotransferase: Shift to High; n=33,36 | 1 | 0 |
| Total Bilirubin: Shift to Low; n=32, 37 | 0 | 1 |
| Total Bilirubin: Shift to High; n=33, 38 | 0 | 0 |
| Gamma-glutamyl Transferase: Shift to Low; n=33, 38 | 0 | 0 |
| Gamma-glutamyl Transferase: Shift to High; n=33,38 | 0 | 0 |
| Blood Urea Nitrogen: Shift to Low; n=33, 38 | 0 | 0 |
| Blood Urea Nitrogen: Shift to High; n=33, 38 | 1 | 1 |
| Creatinine: Shift to Low; n=33, 38 | 0 | 0 |
| Creatinine: Shift to High; n=33, 37 | 0 | 0 |
| Sodium: Shift to Low; n=33, 38 | 0 | 0 |
| Sodium: Shift to High; n=33, 38 | 0 | 0 |
| Potassium: Shift to Low; n=33, 38 | 0 | 0 |
| Potassium: Shift to High; n=33, 38 | 0 | 0 |
| Chloride: Shift to Low; n=33, 38 | 1 | 0 |
| Chloride: Shift to High; n=33, 38 | 0 | 0 |
Temperature increase: \> 38 celcius (C) or ≥ 1 C increase from baseline. Pulse increase: \> 120 beats per minute (bpm) or \> 20 bpm increase from baseline. Pulse decrease: \< 50 bpm or \> 20 bpm decrease from baseline. Systolic blood pressure (SBP) increase: \> 180 millimeters of mercury (mmHg) or \> 40 mmHg from baseline. SBP decrease: \< 90 mmHg or \> 30 mmHg decrease from baseline. Diastolic blood pressure (DBP) increase: \> 105 mmHg or \> 30 mmHg increase from baseline. DBP decrease: \< 50 mmHg or \> 20 mmHg decrease from baseline.
| participants | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Temperature Increase | 0 | 0 |
| Pulse Increase | 1 | 1 |
| Pulse Decrease | 0 | 0 |
| SBP Increase | 1 | 0 |
| SBP Decrease | 0 | 0 |
| DBP Increase | 0 | 1 |
| DBP Decrease | 0 | 0 |
Collected over SAEs: Screening (Within 28 Days Before Day 1) up to Week 4 (Day 28 ±3 Days) or Early Withdrawal. AEs: Day 1 up to Week 4 (Day 28 ±3 Days) or Early Withdrawal. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Non-Pegylated IFN Treated Plus Vaccinations | — | 0/33 (0%) | 14/33 (42.4%) |
| Tecfidera Treated Plus Vaccinations | — | 0/38 (0%) | 11/38 (28.9%) |
| Event | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations |
|---|---|---|
| Injection site painGeneral disorders | 7/33 | 8/38 |
| Injection site erythemaGeneral disorders | 4/33 | 5/38 |
| Injection site swellingGeneral disorders | 3/33 | 3/38 |
| PainGeneral disorders | 3/33 | 1/38 |
| PyrexiaGeneral disorders | 2/33 | 2/38 |
| Urinary tract infectionInfections and infestations | 2/33 | 0/38 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/33 | 0/38 |
| Back painMusculoskeletal and connective tissue disorders | 2/33 | 0/38 |
| HeadacheNervous system disorders | 2/33 | 1/38 |
| RashSkin and subcutaneous tissue disorders | 2/33 | 0/38 |
| Age, Continuous(years) | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations | Total |
|---|---|---|---|
| Mean | 44.7 ± 7.77 | 45.9 ± 6.10 | 45.3 ± 6.91 |
| Sex: Female, Male(Participants) | Non-Pegylated IFN Treated Plus Vaccinations | Tecfidera Treated Plus Vaccinations | Total |
|---|---|---|---|
| Female | 27 | 34 | 61 |
| Male | 6 | 4 | 10 |
Ran from Feb 2015 to primary completion in May 2016, 14 months.
Results were first posted in Jun 2017, 1 year 1 month after primary completion.
Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 14 months is below that.
Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate